Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C17H17Cl2FN4O4S.C7H8O3S |
| Molecular Weight | 635.512 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC=C(C=C1)S(O)(=O)=O.OC2=C(C(Cl)=CC=C2NC(=O)NC3=CC=CC(F)=C3Cl)S(=O)(=O)N4CCNCC4
InChI
InChIKey=CJAUWWGOABMMJX-UHFFFAOYSA-N
InChI=1S/C17H17Cl2FN4O4S.C7H8O3S/c18-10-4-5-13(23-17(26)22-12-3-1-2-11(20)14(12)19)15(25)16(10)29(27,28)24-8-6-21-7-9-24;1-6-2-4-7(5-3-6)11(8,9)10/h1-5,21,25H,6-9H2,(H2,22,23,26);2-5H,1H3,(H,8,9,10)
| Molecular Formula | C7H8O3S |
| Molecular Weight | 172.202 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C17H17Cl2FN4O4S |
| Molecular Weight | 463.311 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Elubrixin (SB-656933) is a CXCR2 antagonist that demonstrates dose-dependent effects on neutrophil activation and recruitment. In preclinical studies, the compound was shown to inhibit CXCL1-induced CD11b up-regulation on PMNs in an in vitro whole blood assay and to be active in in vivo rodent inhalation challenge models of airway inflammation that used endotoxin and ozone to induce airway neutrophilia. Elubrixin was being developed by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease, cystic fibrosis and ulcerative colitis. Elubrixin was withdrawn from the Phase II trial due to the lack of efficacy.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans. | 2011 Aug |
|
| Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis. | 2013 May |
|
| International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. | 2014 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 01:36:22 GMT 2023
by
admin
on
Sat Dec 16 01:36:22 GMT 2023
|
| Record UNII |
13FVR7WD4P
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL2178579
Created by
admin on Sat Dec 16 01:36:22 GMT 2023 , Edited by admin on Sat Dec 16 01:36:22 GMT 2023
|
PRIMARY | |||
|
YY-69
Created by
admin on Sat Dec 16 01:36:22 GMT 2023 , Edited by admin on Sat Dec 16 01:36:22 GMT 2023
|
PRIMARY | |||
|
300000044512
Created by
admin on Sat Dec 16 01:36:22 GMT 2023 , Edited by admin on Sat Dec 16 01:36:22 GMT 2023
|
PRIMARY | |||
|
13FVR7WD4P
Created by
admin on Sat Dec 16 01:36:22 GMT 2023 , Edited by admin on Sat Dec 16 01:36:22 GMT 2023
|
PRIMARY | |||
|
DTXSID60242106
Created by
admin on Sat Dec 16 01:36:22 GMT 2023 , Edited by admin on Sat Dec 16 01:36:22 GMT 2023
|
PRIMARY | |||
|
23634419
Created by
admin on Sat Dec 16 01:36:22 GMT 2023 , Edited by admin on Sat Dec 16 01:36:22 GMT 2023
|
PRIMARY | |||
|
960495-43-6
Created by
admin on Sat Dec 16 01:36:22 GMT 2023 , Edited by admin on Sat Dec 16 01:36:22 GMT 2023
|
PRIMARY | |||
|
C166455
Created by
admin on Sat Dec 16 01:36:22 GMT 2023 , Edited by admin on Sat Dec 16 01:36:22 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |